PMV Pharmaceuticals, Inc.
NASDAQ:PMVPBiotechnology
+$0.04 today
- Market cap
- $65.06M
- Beta
- 1.36
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$1.47
Volume 0.43M
Average 0.38M
PMVP Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
PMV Pharmaceuticals, Inc.NASDAQ: PMVP
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q1 FY2026 research & development of $15.3M fell 12.3% year over year, behind the +8.5% change in trailing-twelve-month research & development. Sequentially, it fell 3.4% from the prior quarter. Over 3 fiscal years it compounded at +10.6% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -12.3% toward the trailing-twelve-month pace of +8.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 69.88M USD
- Year-over-year change
- +21.8%
- 4-year CAGR
- +17.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 69.88M | +21.8% |
| FY2024 | 2024-12-31 | 57.38M | +5.0% |
| FY2023 | 2023-12-31 | 54.63M | +5.7% |
| FY2022 | 2022-12-31 | 51.67M | +42.8% |
| FY2021 | 2021-12-31 | 36.19M | — |
Research & Development vs competitors
How PMVP compares with its peers on the latest reported figures
- PMVP's LTM Mar 2026 research & development of $67.7M is the 4th highest of the 9 companies compared; the peer median is $57.69M.
- Its year-over-year change of +8.5% is the 2nd highest of 9, against a peer median of -8.6%.
- Over three fiscal years its annual growth of +10.6% compares with a peer median of +18.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $200.25M | +133.0% | +35.5% | 78.3% | |
| LTM Mar 2026 | $106.27M | -5.4% | +24.0% | 1163.2% | |
| LTM Mar 2026 | $86.08M | +3.9% | +4.8% | — | |
| LTM Mar 2026 | $67.7M | +8.5% | +10.6% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $59.66M | -11.8% | +35.8% | — |
| LTM Mar 2026 | $55.72M | +5.5% | +12.0% | 29327.4% | |
| LTM Mar 2026 | $48.2M | -55.0% | -0.4% | — | |
CBUSCibus, Inc. | LTM Mar 2026 | $41.12M | -18.1% | +56.4% | 959.3% |
| LTM Mar 2026 | $23.02M | -48.6% | -81.3% | — | |
| Peer median (excluding PMVP) | $57.69M | -8.6% | +18.0% | 1061.2% | |
Competitors are the stored peer set for PMVP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 1.28M | 650K | 1.26M | 1.14M | 0 |
| Gross Profit | (1.28M) | (650K) | (1.26M) | (1.14M) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 36.19M | 51.67M | 54.63M | 57.38M | 69.88M |
| Selling, General & Admin | 20.83M | 24.72M | 24.25M | 26.92M | 16.33M |
| Operating Expenses | 57.01M | 76.39M | 78.88M | 84.3M | 86.21M |
| Depreciation & Amortization | 1.28M | 650K | 1.26M | 1.14M | 133K |
| EBITDA | (56.54M) | (72.68M) | (67.7M) | (73.67M) | (79.78M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (58.29M) | (77.04M) | (80.13M) | (85.45M) | (86.21M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 449K | 3.63M | 11.17M | 10.66M | 6.34M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 470K | 3.71M | 11.17M | 10.64M | 6.29M |
| Income Before Tax | (57.82M) | (73.33M) | (68.96M) | (74.81M) | (79.91M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 23K | (9K) | 2K | (16.1M) | (2.17M) |
| Net Income | (57.85M) | (73.32M) | (68.96M) | (58.71M) | (77.74M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.28) | (1.61) | (1.44) | (1.14) | (1.48) |
| EPS (Diluted) | (1.28) | (1.61) | (1.44) | (1.14) | (1.48) |
| Weighted Avg Shares | 45.14M | 45.59M | 48.01M | 51.58M | 52.54M |
| Weighted Avg Shares (Diluted) | 45.14M | 45.59M | 48.01M | 51.58M | 52.54M |
PMV Pharmaceuticals, Inc.
NASDAQ:PMVP
Intrinsic Alpha fair value
Locked
Current Price
$1.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.